Celltrion, Inc.
Celltrion markets 11 biosimilars including Remsima, Truxima, and Herzuma, plus the new drug Zymfentra (CT-P13 SC).
As of 2026-10-10, Celltrion, Inc. has 35 Korean MFDS drug approvals, 12 US FDA clearances/approvals, 190 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 1991, Celltrion listed on the KOSPI in 2018 as an antibody biosimilar and biopharmaceutical company. It has obtained global marketing approvals for 11 biosimilars including Remsima (CT-P13), Truxima, and Herzuma, and in 2023 received US FDA approval for Zymfentra (CT-P13 SC), the world's first subcutaneous infliximab formulation. In 2025 it recorded sales of KRW 4.1625 trillion and operating profit of KRW 1.1685 trillion, operates a 250,000-liter domestic manufacturing facility plus a 66,000-liter drug-substance facility in Branchburg, US, and completed an integrated development-manufacturing-sales entity through its December 2023 merger with Celltrion Healthcare.
Products & technology
- Remsima (CT-P13)Antibody biosimilar for autoimmune disease treatment
- TruximaAntibody biosimilar
- HerzumaAntibody biosimilar
- Zymfentra (CT-P13 SC)World's first subcutaneous infliximab formulation
Regulatory approvals
data.go.kr · openFDA35 Korean MFDS drug approvals · 2012–2026 / 12 US FDA drug approvals · 2016–2026
- MFDS drugCelltrion Yuflyma Prefilled syringe inj. 20mg/0.2mL2026-02-24Drug · Prescription · Approval202600554
- MFDS drugCelltrion Yuflyma Prefilled syringe inj. 40mg/0.4mL2026-02-24Drug · Prescription · Approval202600555
- FDA drugAVTOZMA2026-01-21FDA drug approval · BLABLA761498
- MFDS drugOmlyclo Pen Inj.(Omalizumab)2025-12-19Drug · Prescription · Approval202503335
- MFDS drugEdardipine Tablets 80/10mg2025-10-29Drug · Prescription · Approval202502797
- MFDS drugEdardipine Tablets 80/5mg2025-10-29Drug · Prescription · Approval202502798
- MFDS drugEdardipine Tablets 40/10mg2025-10-29Drug · Prescription · Approval202502799
- MFDS drugEdardipine Tablets 40/5mg2025-10-29Drug · Prescription · Approval202502800
- FDA drugEYDENZELT2025-10-02FDA drug approval · BLABLA761377
- FDA drugOMLYCLO2025-03-07FDA drug approval · BLABLA761399
- FDA drugOSENVELT2025-02-28FDA drug approval · BLABLA761404
- MFDS drugAvtozma Inj. 80mg2025-02-12Drug · Prescription · Approval202500308
Show 35 more
- MFDS drugAvtozma S.C Inj.2025-02-12Drug · Prescription · Approval202500309
- FDA drugAVTOZMA2025-01-24FDA drug approval · BLABLA761420
- MFDS drugAvtozma Inj.2024-12-20Drug · Prescription · Approval202403038
- FDA drugSTEQEYMA2024-12-17FDA drug approval · BLABLA761338
- MFDS drugStoboclo Pre-filled Syringe2024-11-21Drug · Prescription · Approval202402753
- MFDS drugOsenvelt Injection2024-11-21Drug · Prescription · Approval202402754
- MFDS drugSteqeyma IV Injection2024-09-27Drug · Prescription · Approval202402336
- MFDS drugOmlyclo Pre-filled Syringe Inj.(Omalizumab)2024-06-24Drug · Prescription · Approval202401521
- MFDS drugSteqeyma Pre-filled syringe2024-06-12Drug · Prescription · Approval202401434
- MFDS drugEydenzelt Injection (Aflibercept)2024-05-29Drug · Prescription · Approval202401326
- MFDS drugEydenzelt Pre-filled Syringe (Aflibercept)2024-05-29Drug · Prescription · Approval202401327
- FDA drugZYMFENTRA2023-10-20FDA drug approval · BLABLA761358
- FDA drugYUFLYMA2023-05-23FDA drug approval · BLABLA761219
- MFDS drugCelltrion Yuflyma Pen inj. 40mg/0.4mL2022-11-10Drug · Prescription · Approval202204054
- MFDS drugCelltrion Remsima Pen Inj. 120mg2022-10-28Drug · Prescription · Approval202203940
- MFDS drugVegzelma2022-09-28Drug · Prescription · Approval202203696
- FDA drugVEGZELMA2022-09-27FDA drug approval · BLABLA761268
- MFDS drugYuflyma Prefilled Sysringe Inj. 80mg/0.8mL2022-06-15Drug · Prescription · Approval202202504
- MFDS drugYuflyma Pen inj. 80mg/0.8mL2022-06-15Drug · Prescription · Approval202202505
- MFDS drugCelltrion Remsima Pre-filled Syringe Inj. 120mg2022-03-07Drug · Prescription · Approval202200974
- MFDS drugDonerion Patch 87.5mg(donepezil)2021-11-05Drug · Prescription · Approval202107340
- MFDS drugDonerion Patch 175mg(donepezil)2021-11-05Drug · Prescription · Approval202107341
- MFDS drugYuflyma Prefilled Sysringe Inj. 40mg/0.4mL2021-10-15Drug · Prescription · Approval202106947
- MFDS drugYuflyma Pen inj. 40mg/0.4mL2021-10-15Drug · Prescription · Approval202106948
- MFDS drugRegkirona Inj. 960mg2021-02-05Drug · Prescription · Approval202101124
- MFDS drugRemsima Pen Inj. 120mg2020-10-12Drug · Prescription · Approval202006923
- MFDS drugRemsima Pre-filled Syringe Inj. 120mg2020-02-25Drug · Prescription · Approval202001325
- FDA drugHERZUMA2018-12-14FDA drug approval · BLABLA761091
- FDA drugTRUXIMA2018-11-28FDA drug approval · BLABLA761088
- FDA drugINFLECTRA2016-04-05FDA drug approval · BLABLA125544
- MFDS drugTruxima Inj.2015-07-16Drug · Prescription · Approval201504895
- MFDS drugMycovox Tab. 600mg(for export)Revoked2014-07-31Drug · Prescription · Approval201403539
- MFDS drugHerzuma inj.150mg2014-01-15Drug · Prescription · Approval201400158
- MFDS drugHerzuma inj. 440mg2014-01-15Drug · Prescription · Approval201400159
- MFDS drugRemsima Inj. 100mg2012-07-20Drug · Prescription · Approval201206204
Clinical trials
data.go.kr63 MFDS clinical trial authorisations · 2013–2026 (Phase 1 39 · Phase 3 16 · Phase 1/3 2 · Phase 2 1 · Phase 2/3 1)
- Phase 1CT-P132026-08-31
1 trial site
- Phase 2CT-P392026-08-24
2 trial sites
- Phase 1CT-P682026-07-14
5 trial sites
- Phase 1CT-P452026-06-11
5 trial sites
- Phase 1L03TD12026-03-18
2 trial sites
- Phase 1CT-P722026-02-04
4 trial sites
- Phase 1CT-P522025-11-12
4 trial sites
- Phase 1CT-P732025-11-10
3 trial sites
- Phase 1CT-P522025-08-07
5 trial sites
- Phase 1CT-P712025-07-04
4 trial sites
- Phase 1/3CT-P442025-07-02
15 trial sites
- Phase 1L03TD12025-06-10
2 trial sites
Show 51 more
- Phase 1CT-L022025-05-20
2 trial sites
- Phase 1CT-P702025-05-02
4 trial sites
- Phase 3CT-P512025-04-28
8 trial sites
- Phase 3CT-L022025-04-03
23 trial sites
- Phase 1CT-P432025-03-12
3 trial sites
- Phase 1CT-P6 SC2025-02-27
4 trial sites
- Phase 3CT-P132025-02-21
2 trial sites
- Phase 3CT-P132025-02-21
2 trial sites
- Phase 1CT-L062024-06-10
2 trial sites
- Phase 1CT-L052024-03-14
2 trial sites
- Phase 3L03TD12024-02-19
35 trial sites
- Phase 1CT-L022024-01-09
2 trial sites
- Phase 1CT-L102023-12-01
2 trial sites
- Phase 1CT-L042023-04-24
2 trial sites
- Phase 1CT-P472022-09-28
4 trial sites
- Phase 1CT-L042022-09-23
2 trial sites
- Phase 1CT-L042022-08-10
2 trial sites
- Phase 1CT-L012022-05-13
2 trial sites
- Phase 1CT-L012022-05-13
2 trial sites
- Phase 1CT-L012022-03-29
2 trial sites
- Phase 1CT-L072022-01-14
2 trial sites
- Phase 1CT-P472021-12-06
7 trial sites
- Phase 3CTL0501, CTL05022021-11-17
35 trial sites
- Phase 1CT-P412021-08-03
2 trial sites
- Phase 1CT-L092021-07-20
2 trial sites
- Phase 1CT-L082021-07-19
2 trial sites
- Phase 3CT-P422021-04-30
11 trial sites
- Phase 3CT-P412021-04-29
6 trial sites
- Phase 3CT-P432021-01-07
7 trial sites
- Phase 1CT-P132020-12-09
1 trial site
- Phase 3CT-P592020-10-08
11 trial sites
- Phase 3CT-P392020-10-07
16 trial sites
- Phase 2/3CT-P592020-09-17
19 trial sites
- Phase 1CT-P592020-08-25
4 trial sites
- Phase 1CT-P592020-07-17
1 trial site
- Phase 1bCT-G20정2020-02-26
4 trial sites
- Phase 1CT-P172019-03-06
10 trial sites
- Phase 3CT-P172019-03-06
8 trial sites
- Phase 3CT-P162018-11-07
9 trial sites
- Phase 1CT-G11정, CT-G20정2018-09-18
1 trial site
- Phase 2aCT-P272017-11-13
3 trial sites
- Phase 1CT-P162017-07-17
3 trial sites
- Bioequivalence마이코복스정600밀리그램(리네졸리드)2017-05-30
2 trial sites
- Phase 2bCT-P272016-10-11
40 trial sites
- Phase 1/3CT-P132016-09-06
15 trial sites
- Phase 1CT-P132016-09-06
15 trial sites
- Phase 1CT-P132016-05-04
1 trial site
- Phase 3CT-P102015-09-14
13 trial sites
- Phase 3CT-P102014-08-07
14 trial sites
- Phase 3CT-P102014-06-27
12 trial sites
- Phase 1CT-P102013-02-28
3 trial sites
Global clinical trials
ClinicalTrials.gov · sponsor-matchedPhase 1 · Completed · 2026-05 · NCT07533539
Phase 1 · Completed · 2026-01 · NCT07367958
Phase 1 · Active not recruiting · 2025-09 · NCT07200986
Phase 1 · Completed · 2025-09 · NCT07128654
Phase 1 · Completed · 2025-08 · NCT07158346
Phase 3 · Recruiting · 2025-08 · NCT06952478
Phase 3 · Recruiting · 2025-07 · NCT07093476
Phase 1 · Completed · 2025-05 · NCT06951828
Phase 3 · Active not recruiting · 2025-05 · NCT06630559
Phase 1 · Completed · 2025-03 · NCT06687928
Show 67 more trials
Phase 3 · Active not recruiting · 2025-01 · NCT06939595
Phase 3 · Completed · 2025-01 · NCT06738719
Phase 3 · Completed · 2024-08 · NCT06571591
Phase 1 · Completed · 2024-01 · NCT07054970
Phase 3 · Recruiting · 2024-01 · NCT05906992
Phase 1 · Completed · 2023-06 · NCT05993806
Phase 3 · Unknown · 2023-02 · NCT05725434
Active not recruiting · 2023-01 · NCT05866614
Phase 1 · Unknown · 2022-11 · NCT05617183
Phase 3 · Completed · 2022-11 · NCT05495568
Phase 1 · Completed · 2022-09 · NCT05581693
- A Study to Compare Efficacy and Safety of CT-P47 and RoActemra in Patients With Rheumatoid Arthritis
Phase 3 · Completed · 2022-09 · NCT05489224
Phase 1 · Completed · 2022-09 · NCT05568121
Phase 1 · Completed · 2022-07 · NCT05364164
Phase 3 · Completed · 2022-07 · NCT05385770
Phase 1 · Completed · 2022-06 · NCT05363592
Phase 1 · Completed · 2022-06 · NCT05363384
Phase 3 · Withdrawn · 2022-04 · NCT05224856
Phase 1 · Unknown · 2021-12 · NCT05188378
Phase 1 · Completed · 2021-10 · NCT05017168
Phase 1 · Completed · 2021-10 · NCT06037395
Phase 1 · Completed · 2021-07 · NCT05002244
Phase 1 · Completed · 2021-07 · NCT05009368
Phase 3 · Completed · 2021-07 · NCT04739306
Phase 3 · Completed · 2021-06 · NCT04757376
Phase 3 · Completed · 2021-01 · NCT04673786
Phase 3 · Completed · 2020-12 · NCT04426890
Phase 1 · Terminated · 2020-10 · NCT04418297
Phase 1 · Completed · 2020-10 · NCT04512872
Phase 2/3 · Completed · 2020-10 · NCT04602000
Phase 1 · Completed · 2020-09 · NCT04593641
Phase 3 · Completed · 2020-09 · NCT04205643
Phase 1 · Completed · 2020-08 · NCT04428814
Phase 1 · Completed · 2020-07 · NCT04525079
Phase 1 · Completed · 2020-05 · NCT04018313
Phase 3 · Completed · 2019-10 · NCT03945019
Phase 3 · Completed · 2019-09 · NCT04171414
Phase 1 · Completed · 2019-06 · NCT04295356
Phase 1 · Completed · 2019-05 · NCT03970824
Phase 1 · Completed · 2019-04 · NCT03918967
Phase 3 · Completed · 2019-02 · NCT03676192
Phase 3 · Completed · 2018-11 · NCT03789292
Phase 3 · Completed · 2018-11 · NCT03707535
Phase 1 · Completed · 2018-02 · NCT03446976
Phase 1 · Completed · 2017-08 · NCT03247673
Phase 2 · Terminated · 2016-12 · NCT03511066
Phase 1 · Completed · 2016-09 · NCT02883452
Phase 3 · Completed · 2016-09 · NCT03147248
Phase 1 · Completed · 2015-12 · NCT02665637
Phase 3 · Completed · 2015-11 · NCT02260804
Terminated · 2015-05 · NCT02557308
Terminated · 2014-12 · NCT02326155
Phase 3 · Completed · 2014-09 · NCT02096861
Phase 3 · Completed · 2014-08 · NCT02149121
Phase 3 · Completed · 2014-07 · NCT02162771
Phase 3 · Completed · 2014-06 · NCT02162667
Phase 2 · Completed · 2014-02 · NCT02071914
Terminated · 2013-12 · NCT02557295
Phase 1 · Completed · 2013-05 · NCT01873443
Phase 1 · Completed · 2012-03 · NCT01571206
Phase 3 · Completed · 2012-03 · NCT01571219
Phase 1 · Terminated · 2012-02 · NCT01534949
Phase 1 · Completed · 2012-02 · NCT01534884
Phase 1 · Completed · 2010-10 · NCT01220518
Phase 3 · Completed · 2010-10 · NCT01217086
Phase 3 · Completed · 2010-06 · NCT01084876
Phase 1/2 · Completed · 2010-02 · NCT01084863
R&D and key agreements
Source: DART corporate disclosure차세대 모달리티(ADC, 다중항체 등) · 연구개발 단계 · Developing next-generation modalities such as ADCs and multispecific antibodies through in-house R&D and strategic partnerships
Key disclosures
KRX KIND via OpenDARTShow 78 more events
Publications
PubMed · affiliation-matched- Population Pharmacokinetic Comparability of CT-P16 Versus EU-Avastin® and US-Avastin® in Healthy Subjects and Patients with Non-Squamous Non-Small Cell Lung Cancer.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026-09 · Kim T, Kim H, Lee H 외 4
- Recovery of response and long-term outcomes following loss of response and dose escalation of subcutaneous infliximab: a post hoc analysis of the LIBERTY-CD & LIBERTY-UC trials.
Inflammatory bowel diseases · 2026-07 · Dubinsky MC, Schreiber S, Yarur AJ 외 7
- Symptom Response Dynamics for Personalised Therapy with Subcutaneous Infliximab in Crohn's Disease: Insights from the Randomised, Placebo-Controlled, Phase 3 LIBERTY-CD Trial.
Advances in therapy · 2026-06 · Schreiber S, Sands BE, Danese S 외 5
- Impact of Immunogenicity on Clinical Outcomes in Patients With Moderate-to-Severe Inflammatory Bowel Disease Receiving Subcutaneous Infliximab: A Post Hoc Analysis of the LIBERTY Trials.
United European gastroenterology journal · 2026-04 · Colombel JF, Danese S, Schreiber S 외 6
- Endoscopic Response to Subcutaneous Infliximab by Disease Location: A Post Hoc Analysis of the LIBERTY-CD Study.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2026-04 · Sands BE, Schreiber S, Dubinsky MC 외 9
- Comparative Efficacy and Safety of Advanced Therapies in Maintenance Treatment of Adult Patients with Moderate-to-Severe Crohn's Disease: A Systematic Literature Review and Network Meta-Analysis.
Advances in therapy · 2026-03 · Schreiber S, Danese S, Colombel JF 외 6
- Determination of correlation of clearance with clinical outcomes for inflammatory bowel disease.
World journal of gastroenterology · 2026-02 · Mould DR, Kutschera M, Primas C 외 8
- Pharmacokinetics and safety of candidate biosimilar CT-P55 versus reference secukinumab: a three-arm, randomized, double-blinded, single-dose, multicenter, Phase I study.
Expert opinion on investigational drugs · 2026-01 · Hasunuma T, Yagi M, Nakamichi N 외 7
- Commensal microbe-derived butyrate enhances T follicular helper cell function to boost mucosal vaccine efficacy.
Microbiome · 2026-01 · Ko H, Kim CJ, Choi S 외 13
- Bifidobacterium stercoris KC84 attenuates IBS-D-like symptoms via modulation of serotonin-related pathways and dendritic cell-mediated IFN-β induction.
Current research in microbial sciences · 2026-01 · Song S, Han M, Moon K 외 8
Show 180 more publications
- Subcutaneous infliximab in the treatment of patients with perianal fistulizing Crohn's disease: current evidence and emerging roles.
Therapeutic advances in gastroenterology · 2026-01 · Dignass A, Reenaers C, Buisson A 외 5
- Pharmacokinetics and efficacy of subcutaneous infliximab 120 mg every 2 weeks: a post hoc comparison with intravenous dosing in a phase 1 study in patients with inflammatory bowel disease.
Crohn's & colitis 360 · 2026-01 · Schreiber S, Ye BD, Yu H 외 3
- Discovery and Preclinical Evaluation of PBX-7016, a Methylenedioxy-Camptothecin Payload for Antibody-Drug Conjugates with Enhanced Therapeutic Potential.
Journal of medicinal chemistry · 2026-01 · Chun Y, Lee BS, Kweon S 외 10
- Budget impact of introducing an omalizumab biosimilar in 23 European countries.
Journal of medical economics · 2025-12 · Jang M, Lee J, Yi S 외 1
- A retrospective, multinational, cross-sectional survey of real-world outcomes for patients with axial spondyloarthritis receiving subcutaneous infliximab.
BMC rheumatology · 2025-11 · Baraliakos X, Lee YE, Park S 외 5
- Long-Term Efficacy and Safety of CT-P42 in Patients with Diabetic Macular Edema: 52-Week Results from a Phase 3 Randomized Clinical Trial.
Ophthalmology and therapy · 2025-11 · Brown DM, Wolf S, Veselovsky M 외 19
- Comparing Outcomes With Subcutaneous Infliximab (CT-P13 SC) by Baseline Immunosuppressant Use: A Post Hoc Analysis of the LIBERTY-CD and LIBERTY-UC Studies.
Inflammatory bowel diseases · 2025-10 · Schreiber S, Colombel JF, Hanauer SB 외 14
- Perceived benefits and cost savings of liquid formulation of intravenous infliximab: perspectives of seven European countries.
Expert opinion on biological therapy · 2025-09 · Nam K, Kwon TS, Di Biasio F 외 6
- Correction to: Repeated Switching Between CT-P17 and EU Reference Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Active-Controlled, Phase 3, Interchangeability Study.
Advances in therapy · 2025-09 · Lebwohl MG, Koo JY, Jaworski J 외 17
- Efficacy and Safety of Biosimilar CT-P47 Versus Reference Tocilizumab: 1-Year Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study in Patients with Rheumatoid Arthritis.
Clinical drug investigation · 2025-08 · Burmester G, Trefler J, Racewicz A 외 17
- CT-P39 Compared With Reference Omalizumab in Chronic Spontaneous Urticaria: Results From a Double-Blind, Randomized, Active-Controlled, Phase 3 Study.
Allergy · 2025-08 · Saini SS, Maurer M, Dytyatkovska Y 외 14
- Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Disease: An individual participant data meta-analysis.
Journal of clinical gastroenterology · 2025-08 · Cummings F, Smith PJ, Fumery M 외 6
- Gut microbiota and brain-resident CD4+ T cells shape behavioral outcomes in autism spectrum disorder.
Nature communications · 2025-07 · Park JC, Sim MA, Lee C 외 12
- Efficacy and Safety of Infliximab and Vedolizumab Maintenance Therapy in Patients with Crohn's Disease and Ulcerative Colitis: A Systematic Review and Meta-Analysis.
Journal of clinical medicine · 2025-06 · Sands BE, Peyrin-Biroulet L, Schreiber S 외 12
- Pharmacokinetics and Safety of a Fixed-Dose Combination of Alogliptin and Extended-Release Metformin Under Fasting and/or Fed Conditions in Healthy Adults.
Clinical pharmacology in drug development · 2025-06 · Song JH, Kim JH, Hong JH 외 3
- Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn's disease and ulcerative colitis: 2-year results from open-label extensions of two randomized controlled trials (LIBERTY).
Journal of Crohn's & colitis · 2025-06 · Colombel JF, Sandborn WJ, Schreiber S 외 30
- Efficacy and safety of CT-P39, an omalizumab biosimilar, in chronic spontaneous urticaria: 16-week follow-up study.
Clinical and translational allergy · 2025-06 · Grattan C, Dytyatkovska Y, Springer M 외 15
- CT-P17 Adalimumab Biosimilar in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: An Open-Label Extension of a Phase 3 Interchangeability Study.
Dermatology and therapy · 2025-05 · Pariser DM, Lebwohl MG, Jaworski J 외 15
- A real-world, observational, prospective cohort study evaluating the safety and effectiveness of CT-P13 in inflammatory bowel disease and rheumatoid arthritis: the MEGA-J study.
Current medical research and opinion · 2025-04 · Ishida T, Yokoe I, Obata H 외 3
- Usability, efficacy, and safety of candidate tocilizumab biosimilar CT-P47 self-administration via auto-injector and pre-filled syringe in patients with rheumatoid arthritis: a single-arm, open-label, phase 3 study.
Expert review of clinical immunology · 2025-04 · Burmester G, Klimiuk PA, Trefler J 외 9
- Repeated Switching Between CT-P17 and EU Reference Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Active-Controlled, Phase 3, Interchangeability Study.
Advances in therapy · 2025-03 · Lebwohl MG, Koo JY, Jaworski J 외 17
- A randomized, double-blind, Phase 1, single- and multiple-dose placebo-controlled study of the safety and pharmacokinetics of IN-006, an inhaled antibody treatment for COVID-19 in healthy volunteers.
EBioMedicine · 2025-03 · Moench TR, Botta L, Farrer B 외 14
- Pharmacokinetics and safety of CT‑P39 via auto-injector are comparable to reference omalizumab via pre-filled syringe.
Immunotherapy · 2025-02 · Hasunuma T, Grattan C, Eto T 외 8
- Pharmacokinetics and Safety of Intravenous Candidate Biosimilar CT-P47 and Reference Tocilizumab: A Randomized, Double-Blind, Phase 1 Study.
Journal of clinical pharmacology · 2025-02 · Haranaka M, Eto T, Tanaka T 외 10
- Treatment discontinuation rates due to lack of efficacy through 1 year of maintenance treatment with vedolizumab or subcutaneous infliximab in patients with inflammatory bowel disease: a systematic literature review and meta-analysis.
Therapeutic advances in gastroenterology · 2025-01 · Ferrante M, Peyrin-Biroulet L, Arkkila P 외 14
- Long-term results of a randomized controlled trial of biosimilar CT-P16 and reference bevacizumab in patients with metastatic or recurrent non-small cell lung cancer.
Cancer treatment and research communications · 2025-01 · Andric Z, Moiseenko F, Makharadze T 외 13
- Biosimilar Candidate CT-P42 in Diabetic Macular Edema: 24-Week Results from a Randomized, Active-Controlled, Phase III Study.
Ophthalmology. Retina · 2024-12 · Wolf S, Stanga PE, Veselovsky M 외 19
- Efficacy and safety of candidate biosimilar CT-P41 versus reference denosumab: a double-blind, randomized, active-controlled, Phase 3 trial in postmenopausal women with osteoporosis.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2024-11 · Reginster JY, Czerwinski E, Wilk K 외 15
- Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY).
Gastroenterology · 2024-10 · Hanauer SB, Sands BE, Schreiber S 외 30
- Pharmacokinetic comparison of subcutaneously administered CT-P13 (biosimilar of infliximab) via autoinjector and pre-filled syringe in healthy participants.
Clinical and translational science · 2024-10 · Park YC, Kim JH, Kim SH 외 4
- Efficacy and safety of CT-P47 versus reference tocilizumab: 32-week results of a randomised, active-controlled, double-blind, phase III study in patients with rheumatoid arthritis, including 8 weeks of switching data from reference tocilizumab to CT-P47.
RMD open · 2024-10 · Smolen JS, Trefler J, Racewicz A 외 17
- A randomized, double-blind, single-dose, phase 1 study comparing the pharmacokinetics, pharmacodynamics, safety, and immunogenicity of denosumab biosimilar CT‑P41 and reference denosumab in healthy males.
Expert opinion on biological therapy · 2024-07 · Kim A, Hong JH, Shin W 외 9
- Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 administered by auto-injector or pre-filled syringe: a randomized, open‑label, single-dose phase I study.
Expert opinion on biological therapy · 2024-07 · Yu KS, Ryu H, Shin D 외 14
- Switching from intravenous to subcutaneous infliximab maintenance therapy in inflammatory bowel disease: Post hoc longitudinal analysis of a randomized trial.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2024-07 · Schreiber S, D'Haens G, Cummings F 외 6
- Comparative Efficacy of Subcutaneous and Intravenous Infliximab and Vedolizumab for Maintenance Treatment of TNF-naive Adult Patients with Inflammatory Bowel Disease: A Systematic Literature Review and Network Meta-analysis.
Digestive diseases and sciences · 2024-05 · Peyrin-Biroulet L, Bossuyt P, Bettenworth D 외 9
- Efficacy and safety of biosimilar trastuzumab (CT-P6) in routine clinical practice in the Republic of Korea: a real-world post-marketing surveillance study.
Expert opinion on biological therapy · 2024-04 · Park MH, Seo JH, Park JH 외 18
- Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn's disease and ulcerative colitis included in randomised controlled trials.
BMC gastroenterology · 2024-03 · Peyrin-Biroulet L, Arkkila P, Armuzzi A 외 14
- Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2024-01 · Papp KA, Lebwohl MG, Thaçi D 외 20
- Hedgehog pathway inhibitors for locally advanced and metastatic basal cell carcinoma: A real-world single-center retrospective review.
PloS one · 2024-01 · Patel S, Armbruster H, Pardo G 외 11
- Skin-Whitening Effect of a Callus Extract of Nelumbo nucifera Isolate Haman.
Plants (Basel, Switzerland) · 2023-11 · Moon SH, Kim E, Kim HI 외 7
- Safety and Effectiveness of Regdanvimab for COVID-19 Treatment: A Phase 4 Post-marketing Surveillance Study Conducted in South Korea.
Infectious diseases and therapy · 2023-10 · Lee JY, Bu SH, Song E 외 14
- Safety and effectiveness of intravenous CT-P13 in inflammatory arthritis: post-marketing surveillance study in Thailand.
Immunotherapy · 2023-10 · Mahakkanukrauh A, Chaiamnuay S, Koolvisoot A 외 11
- Efficacy of subcutaneous vs intravenous infliximab in rheumatoid arthritis: a post-hoc analysis of a randomized phase III trial.
Rheumatology (Oxford, England) · 2023-08 · Constantin A, Caporali R, Edwards CJ 외 10
- Cost-effectiveness Analysis of Subcutaneous Infliximab for Inflammatory Bowel Diseases in Sequential Biologic Treatment.
Inflammatory bowel diseases · 2023-06 · Bouhnik Y, Atreya R, Casey D 외 5
- Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 versus reference tocilizumab: a randomized, double-blind, single-dose phase I study.
Expert opinion on investigational drugs · 2023-05 · Yu KS, Kim B, Shin D 외 15
- Early Infliximab Trough Levels Predict the Long-term Efficacy of Infliximab in a Randomized Controlled Trial in Patients with Active Crohn's Disease Comparing, between CT-P13 and Originator Infliximab.
Gut and liver · 2023-05 · Park J, Cheon JH, Lee KM 외 7
- Six-Year Survival Outcomes for Patients with HER2-Positive Early Breast Cancer Treated with CT-P6 or Reference Trastuzumab: Observational Follow-Up Study of a Phase 3 Randomised Controlled Trial.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2023-05 · Stebbing J, Baranau Y, Baryash V 외 13
- Subcutaneous Infliximab Monotherapy Versus Combination Therapy with Immunosuppressants in Inflammatory Bowel Disease: A Post Hoc Analysis of a Randomised Clinical Trial.
Clinical drug investigation · 2023-04 · D'Haens G, Reinisch W, Schreiber S 외 6
- Reduction of oligomer size modulates the competition between cluster formation and phase separation of the tumor suppressor SPOP.
bioRxiv : the preprint server for biology · 2023-03 · Sabri N, Cuneo MJ, Marzahn MR 외 6
- Pharmacokinetics and safety of CT-P17 (40 mg/0.4 ml) versus reference adalimumab: randomized study in healthy Japanese adults.
Immunotherapy · 2023-02 · Haranaka M, Tanaka T, Kim S 외 6
- Real-world clinical effectiveness and safety of CT-P10 in patients with diffuse large B-cell lymphoma: An observational study in Europe.
EJHaem · 2023-02 · Bishton MJ, Salles G, Golfier C 외 13
- A non-interventional, post-marketing surveillance study evaluating the safety and effectiveness of biosimilar rituximab (CT-P10) during routine clinical practice in the Republic of Korea.
Expert opinion on biological therapy · 2023-01 · Jo JC, Jeon Y, Kim D 외 13
- Preclinical assessment and randomized Phase I study of CT-P63, a broadly neutralizing antibody targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Emerging microbes & infections · 2022-12 · Seo JM, Kang B, Song R 외 21
- Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries.
BMC health services research · 2022-11 · Yoo HK, Byun HG, Caprioli F 외 5
- Pharmacokinetic equivalence of CT-P39 and reference omalizumab in healthy individuals: A randomised, double-blind, parallel-group, Phase 1 trial.
Clinical and translational allergy · 2022-11 · Maurer M, Saini SS, McLendon K 외 6
- Candidate Bevacizumab Biosimilar CT-P16 versus European Union Reference Bevacizumab in Patients with Metastatic or Recurrent Non-Small Cell Lung Cancer: A Randomized Controlled Trial.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2022-11 · Verschraegen C, Andric Z, Moiseenko F 외 10
- Palmitoyl‑RGD promotes the expression of dermal‑epidermal junction components in HaCaT cells.
Molecular medicine reports · 2022-10 · Lim JH, Bae JS, Lee SK 외 1
- Stable nebulization and muco-trapping properties of regdanvimab/IN-006 support its development as a potent, dose-saving inhaled therapy for COVID-19.
Bioengineering & translational medicine · 2022-08 · McSweeney MD, Stewart I, Richardson Z 외 13
- The safety and clinical effectiveness of rapid infusion with CT-P10 in patients with non-Hodgkin's lymphoma or chronic lymphocytic leukemia: A retrospective non-interventional post-authorization safety study in Europe.
Hematological oncology · 2022-08 · Bishton M, Marshall S, Harchowal J 외 9
- A Randomized Clinical Trial of Regdanvimab in High-Risk Patients With Mild-to-Moderate Coronavirus Disease 2019.
Open forum infectious diseases · 2022-08 · Kim JY, Săndulescu O, Preotescu LL 외 21
- Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era.
Advances in therapy · 2022-06 · Schreiber S, Ben-Horin S, Alten R 외 10
- Re-Routing Infliximab Therapy: Subcutaneous Infliximab Opens a Path Towards Greater Convenience and Clinical Benefit.
Clinical drug investigation · 2022-06 · Alten R, An Y, Kim DH 외 2
- Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis.
BMC gastroenterology · 2022-06 · Peyrin-Biroulet L, Arkkila P, Armuzzi A 외 13
- Correction to: Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era.
Advances in therapy · 2022-05 · Schreiber S, Ben-Horin S, Alten R 외 10
- A Developer's Perspective on Clinical Evidence and Benefits for Rituximab Biosimilar Uptake, with a Focus on CT-P10.
Clinical drug investigation · 2022-04 · Choi D, Lee S, Kim S 외 1
- Efficacy and safety of switching from reference adalimumab to CT-P17 (100 mg/ml): 52-week randomized, double-blind study in rheumatoid arthritis.
Rheumatology (Oxford, England) · 2022-04 · Furst DE, Jaworski J, Wojciechowski R 외 16
- Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients With Mild-to-Moderate Coronavirus Disease 2019.
Open forum infectious diseases · 2022-04 · Streinu-Cercel A, Săndulescu O, Preotescu LL 외 14
- Efficacy and Safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden Follicular Lymphoma: Final Results of a Randomized Phase III Study.
Clinical lymphoma, myeloma & leukemia · 2022-02 · Kwak LW, Sancho JM, Cho SG 외 20
- Stepping Forward to the Next Level: Totality of Evidence for the First High-Concentration Adalimumab Biosimilar, CT-P17.
Clinical drug investigation · 2022-02 · Viapiana O, Lee S, Yoon S 외 1
- Real-world evidence for subcutaneous infliximab (CT-P13 SC) treatment in patients with ankylosing spondylitis during the coronavirus disease (COVID-19) pandemic: A case series.
Clinical case reports · 2022-01 · Vijayan S, Hwangbo K, Barkham N
- Stable flow-induced expression of KLK10 inhibits endothelial inflammation and atherosclerosis.
eLife · 2022-01 · Williams D, Mahmoud M, Liu R 외 19
- Real-world evidence for subcutaneous infliximab (CT-P13 SC) treatment in patients with psoriatic arthritis during the coronavirus disease (COVID-19) pandemic: A case series.
Clinical case reports · 2022-01 · Baraliakos X, Tsiami S, Vijayan S 외 2
- Monoclonal antibody therapies in the management of SARS-CoV-2 infection.
Expert opinion on investigational drugs · 2022-01 · Miguez-Rey E, Choi D, Kim S 외 2
- An update on the adalimumab biosimilar landscape following the approval of the first high-concentration biosimilar.
Immunotherapy · 2021-12 · Fusaro E, Durez P, Wohlrab J 외 3
- Investigation of the Physicochemical and Biological Stability of the Adalimumab Biosimilar CT-P17.
Advances in therapy · 2021-11 · Shin YK, Han WY, Kim SJ 외 5
- The in vitro and in vivo efficacy of CT-P59 against Gamma, Delta and its associated variants of SARS-CoV-2.
Biochemical and biophysical research communications · 2021-11 · Ryu DK, Kang B, Noh H 외 19
- Sleep, fatigue and alertness during working hours among rotating-shift nurses in Korea: An observational study.
Journal of nursing management · 2021-11 · Min A, Hong HC, Son S 외 1
- Randomised, phase I pharmacokinetic study of adalimumab biosimilar CT-P17 (40 mg/0.4 mL) by autoinjector and prefilled syringe in healthy subjects.
British journal of clinical pharmacology · 2021-11 · Davidson A, Brimhall D, Kay J 외 6
- Safety, Virologic Efficacy, and Pharmacokinetics of CT-P59, a Neutralizing Monoclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Protein: Two Randomized, Placebo-Controlled, Phase I Studies in Healthy Individuals and Patients With Mild SARS-CoV-2 Infection.
Clinical therapeutics · 2021-10 · Kim JY, Jang YR, Hong JH 외 16
- Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study.
Science (New York, N.Y.) · 2021-10 · Hastie KM, Li H, Bedinger D 외 70
- Impact of Infliximab Biosimilar CT-P13 Dose and Infusion Interval on Real-World Drug Survival and Effectiveness in Patients with Ankylosing Spondylitis.
Journal of clinical medicine · 2021-10 · Lee SS, Kim TH, Park W 외 4
- Budget Impact Analysis of the Introduction of Subcutaneous Infliximab (CT-P13 SC) for the Treatment of Rheumatoid Arthritis in the United Kingdom.
Applied health economics and health policy · 2021-09 · Byun HG, Jang M, Yoo HK 외 2
- Long-term efficacy and safety of CT-P10 or rituximab in untreated advanced follicular lymphoma: a randomized phase 3 study.
Blood advances · 2021-09 · Buske C, Jurczak W, Sancho JM 외 12
- Infliximab Biosimilar CT-P13 Observational Studies for Rheumatoid Arthritis, Inflammatory Bowel Diseases, and Ankylosing Spondylitis: Pooled Analysis of Long-Term Safety and Effectiveness.
Advances in therapy · 2021-08 · Cheon JH, Nah S, Kang HW 외 11
- Long-term efficacy and safety of CT-P6 versus trastuzumab in patients with HER2-positive early breast cancer: final results from a randomized phase III trial.
Breast cancer research and treatment · 2021-08 · Stebbing J, Baranau YV, Baryash V 외 11
- Therapeutic effect of CT-P59 against SARS-CoV-2 South African variant.
Biochemical and biophysical research communications · 2021-08 · Ryu DK, Song R, Kim M 외 13
- Pharmacokinetic equivalence of CT-P17 to high-concentration (100 mg/ml) reference adalimumab: A randomized phase I study in healthy subjects.
Clinical and translational science · 2021-07 · Yu KS, Jang IJ, Lim HS 외 17
- Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease.
Gastroenterology · 2021-06 · Schreiber S, Ben-Horin S, Leszczyszyn J 외 15
- Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I/III trial.
Rheumatology (Oxford, England) · 2021-05 · Westhovens R, Wiland P, Zawadzki M 외 19
- Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials.
Arthritis research & therapy · 2021-04 · Combe B, Allanore Y, Alten R 외 10
- Palmitoyl-KVK-L-ascorbic acid conjugate improves matrix abnormality associated with skin aging via epigenetic regulation.
Journal of dermatological science · 2021-03 · Kim MK, Shin MH, Lim JH 외 6
- Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study.
Arthritis research & therapy · 2021-02 · Kay J, Jaworski J, Wojciechowski R 외 15
- A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors.
Investigational new drugs · 2021-02 · Shapiro GI, LoRusso P, Cho DC 외 9
- Effect of Hepatic Impairment on Cobimetinib Pharmacokinetics: The Complex Interplay Between Physiological Changes and Drug Characteristics.
Clinical pharmacology in drug development · 2021-02 · Cheeti S, Deng Y, Chang I 외 6
- Budget Impact Analysis of the Introduction of Rituximab and Trastuzumab Intravenous Biosimilars to EU-5 Markets.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2021-01 · Jang M, Simoens S, Kwon T
- A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein.
Nature communications · 2021-01 · Kim C, Ryu DK, Lee J 외 42
- Efficacy and safety of subcutaneous infliximab versus adalimumab, etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysis.
Expert review of clinical immunology · 2021-01 · Caporali R, Allanore Y, Alten R 외 9
- Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters.
mAbs · 2021-01 · Kim H, Alten R, Cummings F 외 14
- A broad-spectrum and highly potent human monoclonal antibody cocktail for rabies prophylaxis.
PloS one · 2021-01 · Kim PK, Ahn JS, Kim CM 외 15
- A pharmacokinetic evaluation of the rituximab biosimilar CT-P10 in the treatment of rheumatoid arthritis.
Expert opinion on drug metabolism & toxicology · 2020-12 · Yoo DH, Suh CH, Shim SC 외 3
- Quantitative two-photon microscopy imaging analysis of human skin to evaluate enhanced transdermal delivery by hybrid-type multi-lamellar nanostructure: retraction.
Biomedical optics express · 2020-10 · Ahn J, Kim KH, Choe K 외 4
- Post-Marketing Pooled Safety Analysis for CT-P13 Treatment of Patients with Immune-Mediated Inflammatory Diseases in Observational Cohort Studies.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2020-08 · Lee SJ, Baek K, Lee S 외 3
- Correction to: The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases.
Drugs · 2020-07 · Kim H, Alten R, Avedano L 외 16
- Intranasal delivery of cancer-targeting doxorubicin-loaded PLGA nanoparticles arrests glioblastoma growth.
Journal of drug targeting · 2020-07 · Chung K, Ullah I, Kim N 외 7
- A 5-year Retrospective Analysis of Drug Survival, Safety, and Effectiveness of the Infliximab Biosimilar CT-P13 in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis.
Clinical drug investigation · 2020-06 · Kim TH, Lee SS, Park W 외 5
- The Path Towards a Tailored Clinical Biosimilar Development.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2020-06 · Schiestl M, Ranganna G, Watson K 외 6
- WHO implementation workshop on guidelines on procedures and data requirements for changes to approved biotherapeutic products, Seoul, Republic of Korea, 25-26 June 2019.
Biologicals : journal of the International Association of Biological Standardization · 2020-05 · Wadhwa M, Kang HN, Jivapaisarnpong T 외 55
- Some thoughts on the QR method for analytical similarity evaluation.
Journal of biopharmaceutical statistics · 2020-05 · Son S, Oh M, Choo M 외 2
- Retention Rate and Safety of Biosimilar CT-P13 in Rheumatoid Arthritis: Data from the Korean College of Rheumatology Biologics Registry.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2020-02 · Kim HA, Lee E, Lee SK 외 4
- The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases.
Drugs · 2020-02 · Kim H, Alten R, Avedano L 외 16
- Broader neutralization of CT-P27 against influenza A subtypes by combining two human monoclonal antibodies.
PloS one · 2020-01 · Yi KS, Choi JA, Kim P 외 12
- Sparse graphical models via calibrated concave convex procedure with application to fMRI data.
Journal of applied statistics · 2020-01 · Son S, Park C, Jeon Y
- Retention rate and long-term safety of biosimilar CT-P13 in patients with ankylosing spondylitis: data from the Korean College of Rheumatology Biologics registry.
Clinical and experimental rheumatology · 2020-01 · Kim HA, Lee E, Lee SK 외 4
- Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial.
Rheumatology (Oxford, England) · 2019-12 · Shim SC, Božić-Majstorović L, Berrocal Kasay A 외 18
- Design and Analysis of Biosimilar Switching Studies.
Pharmaceutical medicine · 2019-10 · Chow SC, Lee SJ
- Efficacy and safety of CT-P6 versus reference trastuzumab in HER2-positive early breast cancer: updated results of a randomised phase 3 trial.
Cancer chemotherapy and pharmacology · 2019-10 · Esteva FJ, Baranau YV, Baryash V 외 15
- Mechanism of action of the trastuzumab biosimilar CT-P6.
Expert opinion on biological therapy · 2019-10 · Jeong SA, Choi JM, Park JM 외 9
- Induction of Accommodation by Anti-complement Component 5 Antibody-based Immunosuppression in ABO-incompatible Heart Transplantation.
Transplantation · 2019-09 · Park S, Lee JG, Jang JY 외 7
- Glycoprotein 96 polymorphisms are associated with the risk of systemic lupus erythematosus: A case-control study.
International journal of rheumatic diseases · 2019-05 · Lee JS, Im CH, Lee SJ 외 7
- Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study.
Lancet (London, England) · 2019-04 · Ye BD, Pesegova M, Alexeeva O 외 17
- A Randomized, Double-Blind Trial Comparing the Pharmacokinetics of CT-P16, a Candidate Bevacizumab Biosimilar, with its Reference Product in Healthy Adult Males.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2019-04 · Cho SH, Han S, Ghim JL 외 6
- In-Use Stability of the Rituximab Biosimilar CT-P10 (Truxima®) Following Preparation for Intravenous Infusion and Storage.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2019-04 · Kim SJ, Kim KW, Shin YK 외 6
- Safety and efficacy of trastuzumab administered as a 30-min infusion in patients with HER2-positive advanced gastric cancer.
Cancer chemotherapy and pharmacology · 2019-03 · Oh SY, Lee S, Huh SJ 외 11
- Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized Phase III Trial.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2019-02 · Suh CH, Yoo DH, Berrocal Kasay A 외 23
- PDA Biosimilars Workshop Report (September 27-28, 2018)-Getting It Right the First Time for Biosimilar Marketing Applications.
PDA journal of pharmaceutical science and technology · 2019-01 · Krause S, Lacana E, Welch J 외 14
- In-Use Physicochemical and Biological Stability of the Trastuzumab Biosimilar CT-P6 Upon Preparation for Intravenous Infusion.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2018-12 · Kim SJ, Lee JW, Kang HY 외 6
- Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial.
The Lancet. Haematology · 2018-11 · Ogura M, Sancho JM, Cho SG 외 21
- Efficacy and safety of the trastuzumab biosimilar candidate CT-P6.
Future oncology (London, England) · 2018-08 · Esteva FJ, Saeki T, Kim H 외 1
- Quantitative two-photon microscopy imaging analysis of human skin to evaluate enhanced transdermal delivery by hybrid-type multi-lamellar nanostructure.
Biomedical optics express · 2018-08 · Ahn J, Kim KH, Choe K 외 4
- Total pathological complete response versus breast pathological complete response in clinical trials of reference and biosimilar trastuzumab in the neoadjuvant treatment of breast cancer.
Expert review of anticancer therapy · 2018-06 · Stebbing J, Baranau Y, Manikhas A 외 4
- Analytical similarity assessment of rituximab biosimilar CT-P10 to reference medicinal product.
mAbs · 2018-04 · Lee KH, Lee J, Bae JS 외 8
- A randomised trial comparing the pharmacokinetics and safety of the biosimilar CT-P6 with reference trastuzumab.
Cancer chemotherapy and pharmacology · 2018-03 · Esteva FJ, Stebbing J, Wood-Horrall RN 외 3
- Evaluation of analytical similarity between trastuzumab biosimilar CT-P6 and reference product using statistical analyses.
mAbs · 2018-01 · Lee J, Kang HA, Bae JS 외 5
- Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial.
mAbs · 2018-01 · Park W, Božić-Majstorović L, Milakovic D 외 24
- α-Viniferin Improves Facial Hyperpigmentation via Accelerating Feedback Termination of cAMP/PKA-Signaled Phosphorylation Circuit in Facultative Melanogenesis.
Theranostics · 2018-01 · Yun CY, Mi Ko S, Pyo Choi Y 외 10
- Gypenoside UL4-Rich Gynostemma pentaphyllum Extract Exerts a Hepatoprotective Effect on Diet-Induced Nonalcoholic Fatty Liver Disease.
The American journal of Chinese medicine · 2018-01 · Bae UJ, Park EO, Park J 외 6
- Systematic review and meta-analysis of the nitrate reductase assay for drug susceptibility testing of Mycobacterium tuberculosis and the detection limits in liquid medium.
Journal of microbiological methods · 2017-10 · Kwak M, Lee WK, Lim YJ 외 2
- Topical application of palmitoyl-RGD reduces human facial wrinkle formation in Korean women.
Archives of dermatological research · 2017-10 · Bae JS, Kim JM, Kim JY 외 12
- Efficacy, Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10 Versus Innovator Rituximab in Patients with Rheumatoid Arthritis: Results up to Week 72 of a Phase I Randomized Controlled Trial.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2017-08 · Yoo DH, Suh CH, Shim SC 외 18
- Efficacy and Safety of Switching from Innovator Rituximab to Biosimilar CT-P10 Compared with Continued Treatment with CT-P10: Results of a 56-Week Open-Label Study in Patients with Rheumatoid Arthritis.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2017-08 · Park W, Suh CH, Shim SC 외 17
- Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial.
The Lancet. Haematology · 2017-08 · Kim WS, Buske C, Ogura M 외 14
- CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial.
The Lancet. Oncology · 2017-07 · Stebbing J, Baranau Y, Baryash V 외 15
- Anti-complement component 5 antibody targeting MG4 domain inhibits choroidal neovascularization.
Oncotarget · 2017-07 · Jo DH, Kim JH, Yang W 외 7
- Effects of palmitoyl-KVK-L-ascorbic acid on skin wrinkles and pigmentation.
Archives of dermatological research · 2017-07 · Kim HM, An HS, Bae JS 외 10
- Evaluation of the Cross-reactivity of Antidrug Antibodies to CT-P13 and Infliximab Reference Product (Remicade): An Analysis Using Immunoassays Tagged with Both Agents.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2017-06 · Reinisch W, Jahnsen J, Schreiber S 외 7
- Clinical development of CT-P10 and other biosimilar cancer therapeutics.
Future oncology (London, England) · 2017-05 · Kim WS, Coiffier B, Kwon HC 외 1
- An introduction to biosimilar cancer therapeutics: definitions, rationale for development and regulatory requirements.
Future oncology (London, England) · 2017-05 · Buske C, Ogura M, Kwon HC 외 1
- Looking to the future and learning lessons from the recent past: changing stakeholder perceptions of biosimilars in cancer.
Future oncology (London, England) · 2017-05 · Kim WS, Ogura M, Kwon HC 외 1
- Scientific rationale for extrapolation of biosimilar data across cancer indications: case study of CT-P10.
Future oncology (London, England) · 2017-05 · Ogura M, Coiffier B, Kwon HC 외 1
- Comparable Immune Function Inhibition by the Infliximab Biosimilar CT-P13: Implications for Treatment of Inflammatory Bowel Disease.
Journal of Crohn's & colitis · 2017-05 · Lim KJ, Lee SJ, Kim S 외 18
- Characterization of human hybrid cell line, F2N78, through a comparison of culture performances and protein qualities.
Biotechnology letters · 2017-04 · Seo JS, Min BS, Kim YJ 외 5
- Safety and efficacy of CT-P13 in Japanese patients with rheumatoid arthritis in an extension phase or after switching from infliximab.
Modern rheumatology · 2017-03 · Tanaka Y, Yamanaka H, Takeuchi T 외 5
- A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis.
Annals of the rheumatic diseases · 2017-03 · Yoo DH, Suh CH, Shim SC 외 18
- Host Cell Nuclear Localization of Shigella flexneri Effector OspF Is Facilitated by SUMOylation.
Journal of microbiology and biotechnology · 2017-03 · Jo K, Kim EJ, Yu HJ 외 2
- Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study.
Annals of the rheumatic diseases · 2017-02 · Yoo DH, Prodanovic N, Jaworski J 외 12
- Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study.
Annals of the rheumatic diseases · 2017-02 · Park W, Yoo DH, Miranda P 외 14
- Development and characterization of novel chimeric monoclonal antibodies for broad spectrum neutralization of rabies virus.
PloS one · 2017-01 · Kim PK, Keum SJ, Osinubi MOV 외 16
- Switching to biosimilar infliximab (CT-P13): Evidence of clinical safety, effectiveness and impact on public health.
Biologicals : journal of the International Association of Biological Standardization · 2016-07 · Braun J, Kudrin A
- Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima.
Gut · 2016-07 · Ben-Horin S, Yavzori M, Benhar I 외 7
- A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study.
Arthritis research & therapy · 2016-04 · Yoo DH, Racewicz A, Brzezicki J 외 10
- Characteristics of human cell line, F2N78, for the production of recombinant antibody in fed-batch and perfusion cultures.
Journal of bioscience and bioengineering · 2016-03 · Seo JS, Min BS, Kwon YB 외 7
- Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study.
Arthritis research & therapy · 2016-01 · Park W, Yoo DH, Jaworski J 외 12
- Antibodies to the DNA-directed RNA polymerase II subunit RPB1 occur with highest frequency in centenarians.
Immunity & ageing : I & A · 2016-01 · Han J, Park SH, Kim DJ 외 5
- A potent broad-spectrum protective human monoclonal antibody crosslinking two haemagglutinin monomers of influenza A virus.
Nature communications · 2015-07 · Wu Y, Cho M, Shore D 외 22
- Analysis of clinical trials of biosimilar infliximab (CT-P13) and comparison against historical clinical studies with the infliximab reference medicinal product.
Expert review of clinical immunology · 2015-01 · Yoo DH, Oh C, Hong S 외 1
- Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis.
Modern rheumatology · 2015-01 · Takeuchi T, Yamanaka H, Tanaka Y 외 5
- An Anti-Influenza Virus Antibody Inhibits Viral Infection by Reducing Nucleus Entry of Influenza Nucleoprotein.
PloS one · 2015-01 · Yoon A, Yi KS, Chang SY 외 13
- Comparison of immunogenicity test methods used in clinical studies of infliximab and its biosimilar (CT-P13).
Expert review of clinical immunology · 2015-01 · Kim JS, Kim SH, Kwon B 외 1
- Comparison of the pharmacokinetics and safety of three formulations of infliximab (CT-P13, EU-approved reference infliximab and the US-licensed reference infliximab) in healthy subjects: a randomized, double-blind, three-arm, parallel-group, single-dose, Phase I study.
Expert review of clinical immunology · 2015-01 · Park W, Lee SJ, Yun J 외 1
- Scientific rationale behind the development and approval of biosimilar infliximab (CT-P13) in Europe.
Expert review of clinical immunology · 2015-01 · Müller-Ladner U, Hong S, Oh C 외 1
- The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?
Expert review of gastroenterology & hepatology · 2015-01 · Ben-Horin S, Heap GA, Ahmad T 외 3
- Biosimilar infliximab for inflammatory bowel disease: from concepts to clinical practice. Case study illustrated with CT-P13.
Expert review of gastroenterology & hepatology · 2015-01 · Schreiber S, Panés J, Kwon B 외 2
- Biosimilars for the management of rheumatoid arthritis: economic considerations.
Expert review of clinical immunology · 2015-01 · Gulácsi L, Brodszky V, Baji P 외 4
- Case studies on clinical evaluation of biosimilar monoclonal antibody: scientific considerations for regulatory approval.
Biologicals : journal of the International Association of Biological Standardization · 2015-01 · Kudrin A, Knezevic I, Joung J 외 1
- Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea.
Expert review of gastroenterology & hepatology · 2015-01 · Park SH, Kim YH, Lee JH 외 9
- Physicochemical characterization of Remsima.
mAbs · 2014-01 · Jung SK, Lee KH, Jeon JW 외 7
- Cancer vaccines: what do we need to measure in clinical trials?
Human vaccines & immunotherapeutics · 2014-01 · Kudrin A
- Application of a new human cell line, F2N78, in the transient and stable production of recombinant therapeutics.
Biotechnology progress · 2013-01 · Lee HJ, Chang M, Kim JM 외 5
- Characterization of eight novel proteins with male germ cell-specific expression in mouse.
Reproductive biology and endocrinology : RB&E · 2008-07 · Baek N, Woo JM, Han C 외 5
- Modeling and optimization of biopolymer (polyhydroxyalkanoates) production from ice cream residue by novel statistical experimental design.
Applied biochemistry and biotechnology · 2006-05 · Lee KM, Gilmore DF
Patents
KIPRIS · applicant-matchedPublished · 2026-02 · Application 1020260037185
Published · 2025-12 · Application 1020250208913
PCT · Published · 2025-12 · Application PCT/KR2025/020633
PCT · Published · 2025-09 · Application PCT/KR2025/015305
Published · 2025-09 · Application 1020250141633
PCT · Published · 2025-08 · Application PCT/KR2025/012835
Published · 2025-08 · Application 1020250117811
Published · 2025-07 · Application 1020250097767
PCT · Published · 2025-07 · Application PCT/KR2025/010662
Published · 2025-06 · Application 1020250081791
Show 295 more patents
PCT · Published · 2025-06 · Application PCT/KR2025/008598
TW · Published · 2025-06 · Application 114123096
Published · 2025-05 · Application 1020250059387
Published · 2025-04 · Application 1020250054820
PCT · Published · 2025-04 · Application PCT/KR2025/095295
PCT · Published · 2025-04 · Application PCT/KR2025/004384
Published · 2025-03 · Application 1020250027537
TW · Published · 2024-12 · Application 113151324
Published · 2024-12 · Application 1020240199263
PCT · Published · 2024-12 · Application PCT/KR2024/021358
Published · 2024-12 · Application 1020240192442
Published · 2024-12 · Application 1020240191804
Published · 2024-12 · Application 1020240178711
US · Published · 2024-11 · Application 18959294
Registered · 2024-11 · Application 1020240168437
TW · Published · 2024-10 · Application 113140010
TW · Published · 2024-10 · Application 113140012
TW · Published · 2024-10 · Application 113140011
CN · Published · 2024-10 · Application 202480067227.X
CN · Published · 2024-10 · Application 202480067172.2
CN · Published · 2024-10 · Application 202480067238.8
Published · 2024-10 · Application 1020240142888
Published · 2024-10 · Application 1020240143157
Published · 2024-10 · Application 1020240143183
EP · Published · 2024-10 · Application 24880198.7
EP · Published · 2024-10 · Application 24880196.1
EP · Published · 2024-10 · Application 24880188.8
PCT · Published · 2024-10 · Application PCT/KR2024/015905
PCT · Published · 2024-10 · Application PCT/KR2024/015890
PCT · Published · 2024-10 · Application PCT/KR2024/015907
Published · 2024-09 · Application 1020240132026
Published · 2024-09 · Application 1020240131000
EP · Published · 2024-08 · Application 24856850.3
PCT · Published · 2024-08 · Application PCT/KR2024/012605
US · Published · 2024-07 · Application 18774066
US · Published · 2024-04 · Application 18638633
Published · 2024-04 · Application 1020240045246
PCT · Published · 2024-03 · Application PCT/KR2024/004037
Published · 2024-03 · Application 1020240042240
EP · Published · 2024-03 · Application 24775265.2
PCT · Published · 2024-03 · Application PCT/KR2024/095560
US · Published · 2024-03 · Application 18593012
US · Published · 2024-02 · Application 19159277
EP · Published · 2024-02 · Application 24764160.8
PCT · Published · 2024-02 · Application PCT/KR2024/002482
Published · 2024-02 · Application 1020240021944
US · Published · 2024-02 · Application 18434346
TW · Published · 2023-08 · Application 112132410
Published · 2023-08 · Application 1020230113356
PCT · Published · 2023-08 · Application PCT/KR2023/012762
Published · 2023-08 · Application 1020230110838
Published · 2023-03 · Application 1020230035180
Published · 2023-02 · Application 1020230026293
PCT · Published · 2022-12 · Application PCT/KR2022/021574
TW · Published · 2022-10 · Application 111138133
Published · 2022-10 · Application 1020220128235
PCT · Published · 2022-10 · Application PCT/KR2022/015081
Registered · 2022-08 · Application 1020220103648
Published · 2022-04 · Application 1020220043116
PCT · Published · 2022-04 · Application PCT/KR2022/004997
Published · 2022-03 · Application 1020220040847
US · Registered · 2022-01 · Application 18271946
EP · Published · 2022-01 · Application 22739715.5
PCT · Published · 2022-01 · Application PCT/KR2022/000646
Published · 2021-12 · Application 1020210193011
US · Published · 2021-12 · Application 18269549
EP · Published · 2021-12 · Application 21915835.9
CN · Published · 2021-08 · Application 202180053644.5
TW · Published · 2021-08 · Application 110131972
Published · 2021-08 · Application 1020210115096
EP · Published · 2021-08 · Application 21862153.0
Published · 2021-08 · Application 1020210105647
Published · 2021-08 · Application 1020210103145
TW · Registered · 2021-07 · Application 110127998
CN · Published · 2021-07 · Application 202180058213.8
US · Published · 2021-07 · Application 18019020
Published · 2021-07 · Application 1020210099769
EP · Published · 2021-07 · Application 21851412.3
US · Published · 2021-07 · Application 18006417
Published · 2021-07 · Application 1020210097373
EP · Published · 2021-07 · Application 21845495.7
Published · 2021-07 · Application 1020210096237
Published · 2021-07 · Application 1020210093171
Withdrawn · 2021-06 · Application 1020210075093
Withdrawn · 2021-06 · Application 1020210075095
CN · Published · 2021-04 · Application 202180022157.2
US · Registered · 2021-04 · Application 17917285
Published · 2021-04 · Application 1020210052622
EP · Published · 2021-04 · Application 21792544.5
Withdrawn · 2021-03 · Application 1020210041251
Withdrawn · 2021-03 · Application 1020210040750
CN · Published · 2021-03 · Application 202180010840.4
Registered · 2021-03 · Application 1020210039212
Withdrawn · 2021-03 · Application 1020210036902
US · Registered · 2021-03 · Application 17913182
EP · Published · 2021-03 · Application 21774952.2
PCT · Published · 2021-03 · Application PCT/KR2021/003498
US · Registered · 2021-03 · Application 17202982
Registered · 2021-03 · Application 1020210029750
CN · Published · 2021-03 · Application 202180017884.X
Withdrawn · 2021-03 · Application 1020210027772
EP · Published · 2021-03 · Application 21760612.8
Withdrawn · 2021-02 · Application 1020210019481
Withdrawn · 2021-02 · Application 1020210019449
Withdrawn · 2021-01 · Application 1020210013681
Published · 2021-01 · Application 1020210005339
Withdrawn · 2021-01 · Application 1020210004236
Published · 2020-12 · Application 1020200188193
Withdrawn · 2020-12 · Application 1020200185224
Withdrawn · 2020-12 · Application 1020200182215
- Expression cassettes comprising introns for high expression of proteins of interest and uses thereof
CN · Published · 2020-12 · Application 202080087756.8
US · Registered · 2020-12 · Application 17784461
CN · Published · 2020-12 · Application 202080088988.5
Withdrawn · 2020-12 · Application 1020200176961
US · Published · 2020-12 · Application 17780898
Withdrawn · 2020-12 · Application 1020200171999
Withdrawn · 2020-11 · Application 1020200152212
Withdrawn · 2020-11 · Application 1020200152158
Withdrawn · 2020-11 · Application 1020200152180
Registered · 2020-11 · Application 1020200152186
Withdrawn · 2020-11 · Application 1020200145587
PCT · Published · 2020-09 · Application PCT/US2020/052524
Registered · 2020-09 · Application 1020200113415
Rejected · 2020-08 · Application 1020200110695
Registered · 2020-08 · Application 1020200108887
Withdrawn · 2020-08 · Application 1020200104966
TW · Registered · 2020-07 · Application 109124333
Withdrawn · 2020-07 · Application 1020200089019
Registered · 2020-06 · Application 1020200080638
Withdrawn · 2020-04 · Application 1020200043685
Withdrawn · 2020-03 · Application 1020200034749
Published · 2020-02 · Application 1020200024817
TW · Published · 2020-02 · Application 109106508
Registered · 2020-02 · Application 1020200023931
Registered · 2019-12 · Application 1020190172454
CN · Published · 2019-11 · Application 201980076701.4
Withdrawn · 2019-11 · Application 1020217012368
CN · Published · 2019-09 · Application 201980061915.4
TW · Published · 2019-09 · Application 108134081
Registered · 2019-09 · Application 1020190116219
Registered · 2019-07 · Application 1020190086808
US · Registered · 2019-07 · Application 17261145
EP · Published · 2019-07 · Application 19837708.7
Registered · 2019-04 · Application 1020190045908
Registered · 2018-12 · Application 1020180165984
CN · Published · 2018-11 · Application 201880088236.1
US · Published · 2018-11 · Application 16966248
Registered · 2018-11 · Application 1020180152779
EP · Published · 2018-11 · Application 18903480.4
Rejected · 2018-11 · Application 1020180146218
Withdrawn · 2018-11 · Application 1020180143155
Withdrawn · 2018-11 · Application 1020180138228
CN · Published · 2018-10 · Application 201880076531.5
Registered · 2018-10 · Application 1020180121090
US · Registered · 2018-09 · Application 16130405
Withdrawn · 2018-09 · Application 1020180108125
TW · Registered · 2018-08 · Application 107130340
TW · Published · 2018-08 · Application 114103576
CN · Published · 2018-08 · Application 201880055961.9
Registered · 2018-08 · Application 1020180102233
Registered · 2018-07 · Application 1020180086393
Withdrawn · 2018-06 · Application 1020180070955
Registered · 2018-04 · Application 1020180048810
Registered · 2018-03 · Application 1020180035919
Withdrawn · 2018-02 · Application 1020180021414
Withdrawn · 2018-02 · Application 1020180017449
Withdrawn · 2018-01 · Application 1020180004162
TW · Registered · 2018-01 · Application 107101082
CN · Published · 2018-01 · Application 201880006548.3
CN · Published · 2018-01 · Application 202510620835.5
Registered · 2018-01 · Application 1020180003303
US · Registered · 2018-01 · Application 16477187
EP · Registered · 2018-01 · Application 18738894.7
Registered · 2018-01 · Application 1020180002862
Registered · 2017-12 · Application 1020170180825
Withdrawn · 2017-12 · Application 1020170180869
TW · Registered · 2017-10 · Application 106137110
Withdrawn · 2017-10 · Application 1020170140270
TW · Registered · 2017-10 · Application 106134242
Registered · 2017-09 · Application 1020170113144
CN · Published · 2017-08 · Application 201780062284.9
TW · Registered · 2017-08 · Application 106126967
Registered · 2017-08 · Application 1020170100975
Registered · 2017-07 · Application 1020170091965
CN · Published · 2017-06 · Application 201780036776.0
TW · Registered · 2017-06 · Application 106121657
Withdrawn · 2017-06 · Application 1020170081814
US · Registered · 2017-06 · Application 16310585
EP · Registered · 2017-06 · Application 17820536.5
EP · Published · 2017-06 · Application 24152383.6
US · Registered · 2017-05 · Application 15606628
CN · Published · 2017-03 · Application 201780021588.0
Expired · 2017-03 · Application 1020170030571
Expired · 2017-03 · Application 1020170030569
Withdrawn · 2017-02 · Application 1020170023630
TW · Registered · 2017-02 · Application 106104942
US · Registered · 2017-01 · Application 15400294
Registered · 2017-01 · Application 1020170001662
Withdrawn · 2016-12 · Application 1020160170635
Registered · 2016-11 · Application 1020160150961
Registered · 2016-10 · Application 1020160127375
Withdrawn · 2016-09 · Application 2020160005383
US · Registered · 2016-09 · Application 15259823
CN · Published · 2016-09 · Application 201680052098.2
Registered · 2016-08 · Application 1020160112156
Registered · 2016-08 · Application 1020160102961
Registered · 2016-08 · Application 1020160102977
Registered · 2016-08 · Application 1020160103034
Registered · 2016-08 · Application 1020160102950
Registered · 2016-08 · Application 1020160102972
Registered · 2016-08 · Application 1020160102986
Registered · 2016-08 · Application 1020160103039
Registered · 2016-08 · Application 1020160103028
Registered · 2016-08 · Application 1020160103020
Registered · 2016-08 · Application 1020160102965
Registered · 2016-06 · Application 1020177035546
US · Registered · 2016-06 · Application 15735569
Registered · 2016-06 · Application 1020160071948
US · Registered · 2016-06 · Application 15735068
PCT · Published · 2016-06 · Application PCT/KR2016/006145
Registered · 2016-05 · Application 1020160065148
Registered · 2016-03 · Application 1020160038898
Registered · 2016-03 · Application 1020160038651
Registered · 2016-03 · Application 1020160038630
Registered · 2016-03 · Application 1020160038168
Registered · 2016-02 · Application 1020160017091
Registered · 2015-12 · Application 1020150189659
US · Registered · 2015-12 · Application 15540344
EP · Published · 2015-12 · Application 15875728.6
PCT · Published · 2015-12 · Application PCT/KR2015/014504
Registered · 2015-12 · Application 1020150172803
EP · Registered · 2015-12 · Application 15866215.5
CN · Published · 2015-11 · Application 201580064775.8
Registered · 2015-11 · Application 1020150167036
US · Registered · 2015-11 · Application 15529828
EP · Published · 2015-11 · Application 20188695.9
EP · Published · 2015-11 · Application 15864087.0
Registered · 2015-10 · Application 1020150147473
Registered · 2015-09 · Application 1020150126832
Withdrawn · 2015-08 · Application 1020150113515
Registered · 2015-06 · Application 1020150092848
Registered · 2015-06 · Application 1020150082625
US · Published · 2015-05 · Application 15533269
Registered · 2015-03 · Application 1020150044636
Registered · 2014-12 · Application 1020140178030
PCT · Published · 2014-12 · Application PCT/KR2014/012171
Registered · 2014-10 · Application 1020140144667
Registered · 2014-09 · Application 1020140115009
Registered · 2014-07 · Application 1020140097045
CN · Published · 2014-05 · Application 201480030049
Registered · 2014-05 · Application 1020140061977
Expired · 2014-04 · Application 1020140051171
Registered · 2014-03 · Application 1020140036601
US · Registered · 2014-03 · Application 14780682
EP · Registered · 2014-03 · Application 14774436.1
Registered · 2014-02 · Application 1020140021708
Expired · 2014-01 · Application 1020140000820
Expired · 2014-01 · Application 1020140000819
Expired · 2014-01 · Application 1020140000818
CN · Published · 2014-01 · Application 201480003980
Registered · 2013-12 · Application 1020130157234
Withdrawn · 2013-12 · Application 1020130148247
CN · Published · 2013-09 · Application 201380048896
Registered · 2013-09 · Application 1020130111137
Withdrawn · 2013-05 · Application 1020130055409
Registered · 2013-05 · Application 1020130055401
Withdrawn · 2013-03 · Application 1020130030055
Expired · 2013-02 · Application 1020130017585
Rejected · 2012-12 · Application 1020120144082
CN · Published · 2012-09 · Application 201280047216
CN · Published · 2012-09 · Application 201280047234
Registered · 2012-09 · Application 1020120107512
Registered · 2012-09 · Application 1020120107514
US · Registered · 2012-09 · Application 14348284
EP · Registered · 2012-09 · Application 12835569.0
Registered · 2012-03 · Application 1020120026835
Withdrawn · 2011-11 · Application 1020110125847
Registered · 2011-03 · Application 1020110020061
EP · Published · 2011-03 · Application 16175875.0
EP · Published · 2011-03 · Application 14181741.1
PCT · Published · 2011-03 · Application PCT/KR2011/001563
Registered · 2011-02 · Application 1020110013931
Registered · 2010-11 · Application 1020100113663
Registered · 2010-04 · Application 1020100038745
Registered · 2010-03 · Application 1020100028222
EP · Registered · 2009-04 · Application 09729465.6
PCT · Published · 2009-04 · Application PCT/KR2009/001856
Registered · 2008-04 · Application 1020080033972
Expired · 2007-10 · Application 1020070108451
Rejected · 2006-03 · Application 1020060020723
EP · Registered · 2006-03 · Application 06716203.2
Withdrawn · 2005-11 · Application 1020050110877
Expired · 2005-06 · Application 1020050057135
Rejected · 2001-07 · Application 1020010042737
Expired · 2001-07 · Application 1020010042740
AI reads
MAA server logs · IP-verifiedPulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.
Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.
Collected as raw material for future answers.
Queries from users who connected this index to their own AI.
- OpenAIChatGPT-Userlive2
- OpenAIOAI-SearchBot73
- PerplexityPerplexityBot4
- AnthropicClaudeBot2
- MicrosoftBingbot1
- GoogleGoogleOther1
Measured since Aug 27, 2026 · 5 AI engines · last read Oct 9, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.
Connect this company index directly to your AI
Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for Celltrion, Inc. and every listed Korean medical, bio and AI company.
How to connect (MCP)Companies in the same categoryPharma & CDMO
Founded in 1941 and listed on the KOSPI in 1975, Ildong Holdings is the holding company of the Ildong Pharmaceutical Group, overseeing pharmaceutical, aesthetic medical device, and drug development affiliates.
Founded in 1941 and listed on the KOSPI in 1975, Yuyu Pharma is a pharmaceutical company with a co-promotion agreement with Dong-A ST for Tanamin.
Founded and listed on the KOSPI in 2016, Il Dong Pharmaceutical manufactures products including the Aronamin vitamin line.
Founded 2000, KOSDAQ-listed 2009, Medy-Tox develops and exports botulinum toxin biopharmaceuticals including Meditoxin and Innotox.
KOSPI-listed comprehensive pharmaceutical company specializing in blood products and vaccines, with FDA-approved immunoglobulin ALYGLO.
KOSPI-listed pharmaceutical company behind Coldwon cold medicine and Jangdaewon probiotics, developing a P-CAB drug pipeline.
Founded 2011, listed 2016 — Samsung Biologics is a biopharma CDMO with 785,000L capacity across five Songdo plants.
Founded in 2006 and listed on KOSDAQ in 2020, Genolution is a molecular diagnostics and RNAi company producing nucleic acid extraction reagents and devices.
Ahn-Gook Pharmaceutical sells the cough/expectorant drug Sinecuran and the eye-health supplement Tobicom.
Founded in 2003 and listed on KOSDAQ in 2015, Corestem Chemon develops stem cell therapies and provides nonclinical CRO services, including the ALS treatment Neuronata-R.
Founded 2005, KOSDAQ-listed 2022, BIO-FD&C develops plant-cell platform-based cosmeceutical materials and biopharma pipelines.
KOSPI-listed comprehensive pharma company behind Amaryl diabetes drug and the USD 86.25M HL5101 anticancer out-license deal.
Sources and updates
Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- Approvals & clinical trials
- Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
- Key disclosures
- KRX KIND via OpenDART exchange filings — updated daily
- Global clinical trials
- ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
- Financials
- DART corporate disclosure filings — annual
- Publications
- PubMed (US National Library of Medicine) — affiliation-matched, updated daily
- Patents
- KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
- AI reads
- Our server logs, IP-verified every 6 hours
- AI visibility
- Measured 2026-10-01
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition